Page last updated: 2024-08-23

bezafibrate and Acute Myelogenous Leukemia

bezafibrate has been researched along with Acute Myelogenous Leukemia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Alhazmi, B; Beke, F; Bunce, CM; di Maio, A; Drayson, MT; Francis, T; Jiang, Y; Khanim, FL; Radotra, A; Southam, AD; Trova, S1
Bambery, KR; Denbigh, JL; Drayson, MT; Goodacre, R; Khanim, FL; Lockyer, NP; Perez-Guaita, D; Southam, AD; Tobin, MJ; Vernooij, RR; Wood, BR; Xu, Y1
Birtwistle, J; Bunce, CM; Davies, NJ; Drayson, MT; Green, RM; Gunther, UL; Hayden, RE; Khanim, FL; Lodi, A; Mountford, JC; Murray, JA; Ride, JP; Schrewe, H; Tiziani, S; Viant, MR1
Bunce, CM; Craddock, CF; Drayson, MT; Hayden, RE; Holyoake, TL; Jackson, N; Khanim, FL; Lumley, M; Murray, JA1

Trials

1 trial(s) available for bezafibrate and Acute Myelogenous Leukemia

ArticleYear
Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML).
    British journal of haematology, 2010, Volume: 149, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bezafibrate; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Medroxyprogesterone Acetate; Middle Aged; Recurrence; Treatment Outcome

2010

Other Studies

3 other study(ies) available for bezafibrate and Acute Myelogenous Leukemia

ArticleYear
Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing.
    British journal of cancer, 2022, Volume: 126, Issue:2

    Topics: Anticonvulsants; Antioxidants; Bezafibrate; Cell Line, Tumor; Contraceptive Agents, Hormonal; Humans; Hypolipidemic Agents; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Medroxyprogesterone Acetate; NF-E2-Related Factor 2; Reactive Oxygen Species; Valproic Acid

2022
Probing the action of a novel anti-leukaemic drug therapy at the single cell level using modern vibrational spectroscopy techniques.
    Scientific reports, 2017, 06-01, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bezafibrate; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Medroxyprogesterone; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Synchrotrons

2017
Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.
    PloS one, 2009, Dec-07, Volume: 4, Issue:12

    Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bezafibrate; Cell Differentiation; Cell Line, Tumor; Cholecalciferol; Drug Screening Assays, Antitumor; Glutathione; Humans; Hydroxyprostaglandin Dehydrogenases; I-kappa B Proteins; Leukemia, Myeloid, Acute; Medroxyprogesterone Acetate; PPAR gamma; Prostaglandin D2; Reactive Oxygen Species; Vitamin A

2009
chemdatabank.com